Catalina wins sales rights to NutraLec

Lectin Labs has given California-based Catalina Lifesciences the sales rights in the US for NutraLec, a dietary supplement for gastrointestinal health.

"We are highly gratified by the success we have seen with NutraLec in the support of gastric health, and we are very excited to have a partner like Catalina Lifesciences, which is ideally positioned to make this important new product available to the entire medical community," said Bruce Rose, chairman and CEO of Lectin Labs.

NutraLec is a lectin product, derived from wheat. Lectins are specialized proteins which occur naturally and have unique binding properties. Lectin Labs has identified certain botanical lectins which have the ability to safely bind with invading organisms allowing them to be naturally eliminated.

Catalina's marketing strategy will include direct detailing to physicians nationwide as well as distribution through the Kaiser Permanente Pharmacy Division of 600 pharmacies.

NutraLec was introduced two years ago by Lectin Labs after several years researching the product's potential as a treatment for gastritis and ulcers caused by H. pylori bacteria.

NutraLec is available as a bulk powder to manufacturers for use in such products as antacids and dietary supplements.